Marshall Wace’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

Marshall Wace’s Portfolio CALT Stock Details CALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-27,910	Closed	-$518K	–	3957
2022 Q1	$518K	Sell	27,910 -52,763	-65%	-$1.06M	﹤0.01%	2757
2021 Q4	$2M	Buy	+80,673	New	+$1.62M	﹤0.01%	2047
2021 Q2	–	Sell	-7,887	Closed	-$218K	–	3202
2021 Q1	$218K	Buy	+7,887	New	+$236K	﹤0.01%	2234

Other funds holding CALT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

IIM

Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Marshall Wace's CALT Position: Q2 2022 in Review

Marshall Wace sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q2 2022, closing a stake of 27,910 shares — an estimated $518K sold.

Marshall Wace first reported a position in CALT in Q1 2021 and held it in 3 quarters. The position peaked at $2M in Q4 2021. 16 funds tracked by Wall St. Rank hold CALT as of Q2 2022.

Marshall Wace reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q2 2022 after selling out during the quarter.
Marshall Wace sold 27,910 Calliditas Therapeutics AB American Depositary Shares shares in Q2 2022, an estimated $518K.
Marshall Wace first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q1 2021 and held it in 3 quarters.
Marshall Wace's Calliditas Therapeutics AB American Depositary Shares position peaked at $2M in Q4 2021.
16 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q2 2022.

Based on Marshall Wace's 13F filing for Q2 2022, filed 15 Aug 2022.